Quetiapine-d8 fumarate | CAS#1185247-12-4 | Quetiapine quantification internal standard

MedKoo Cat#: 463668 | Name: Quetiapine-d8 fumarate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quetiapine-d8 fumarate is intended for use as an internal standard for the quantification of quetiapine by GC- or LC-MS. Quetiapine is an atypical, second generation antipsychotic compound. It has effects at multiple receptors, antagonizing dopamine D1, D2, and D3 receptors, serotonin 5-HT1A, 5-HT2A, and 5-HT7 receptors, and α1A, α1B, and α2C adrenergic receptors. Quetiapine also potently antagonizes the histamine H1 receptor.

Chemical Structure

Quetiapine-d8 fumarate

CAS#1185247-12-4 (fumarate)

Theoretical Analysis

MedKoo Cat#: 463668

Name: Quetiapine-d8 fumarate

CAS#: 1185247-12-4 (fumarate)

Chemical Formula: C25H21D8N3O6S

Exact Mass: 507.2279

Molecular Weight: 507.63

Elemental Analysis: C, 59.15; H, 7.34; N, 8.28; O, 18.91; S, 6.32

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Quetiapine-d8 fumarate; Quetiapine d8 fumarate;

IUPAC/Chemical Name

2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)ethoxy)ethan-1-ol fumarate

InChi Key

VRHJBWUIWQOFLF-SMODUGIXSA-N

InChi Code

InChI=1S/C21H25N3O2S.C4H4O4/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;2-1+/i9D2,10D2,11D2,12D2;

SMILES Code

OC(/C=C/C(O)=O)=O.OCCOCCN(C([2H])(C([2H])(N1C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3)[2H])[2H])C([2H])(C1([2H])[2H])[2H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, DMF, and methanol

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Quetiapine is an atypical, second generation antipsychotic compound. It has effects at multiple receptors, antagonizing dopamine D1, D2, and D3 receptors, serotonin 5-HT1A, 5-HT2A, and 5-HT7 receptors, and α1A, α1B, and α2C adrenergic receptors. Quetiapine also potently antagonizes the histamine H1 receptor.

In vitro activity:

In 47 plasma samples from patients prescribed quetiapine (prescribed dose 200-950 mg/day), the (median, range) concentrations found (µg/L) were: quetiapine 83 (7-748), N-desalkylquetiapine, 127 (7-329), O-desalkylquetiapine 12 (2-37), 7-hydroxyquetiapine 3 (<1-48), and quetiapine sulfoxide 3,379 (343-21,704). The analyte concentrations found were comparable to those reported by others except that the concentrations of the sulfoxide were markedly higher. The reason for this discrepancy in unclear. Reference: Biomed Chromatogr. 2012 Sep;26(9):1125-32. https://pubmed.ncbi.nlm.nih.gov/22241669/

In vivo activity:

As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia and related disorders, despite their side effects, including weight gain. Because centrally acting H(1)-histamine receptor antagonists are known to induce weight gain with chronic use, and because H(1)-histamine receptor affinities are positively correlated with weight gain among typical and atypical antipsychotic drugs, it is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H(1)-histamine receptors. Quetiapine potently antagonizes the histamine H(1)-histamine receptor. Reference: Neuropsychopharmacology. 2003 Mar;28(3):519-26. https://pubmed.ncbi.nlm.nih.gov/12629531/

	Solvent	mg/mL	mM
Solubility
	DMF	0.0	0.00
	DMSO	0.0	0.00
	Methanol	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 507.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS. Biomed Chromatogr. 2012 Sep;26(9):1125-32. doi: 10.1002/bmc.2672. Epub 2012 Jan 12. PMID: 22241669. 2. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027. PMID: 12629531.

In vitro protocol:

Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS. Biomed Chromatogr. 2012 Sep;26(9):1125-32. doi: 10.1002/bmc.2672. Epub 2012 Jan 12. PMID: 22241669.

In vivo protocol:

Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027. PMID: 12629531.

1: Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS. Biomed Chromatogr. 2012 Sep;26(9):1125-32. doi: 10.1002/bmc.2672. Epub 2012 Jan 12. PMID: 22241669. 2: Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027. PMID: 12629531.